The primary purpose of the study is to investigate the anti-dyskinetic effect of several doses of sarizotan in Parkinson patients in order to generate information on the dose-response relationship (dose-finding).
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Enrollment
360
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Unnamed facility
Fountain Valley, California, United States
Unnamed facility
Sunnyvale, California, United States
Unnamed facility
Miami, Florida, United States
Unnamed facility
Tampa, Florida, United States
Unnamed facility
Atlanta, Georgia, United States
Unnamed facility
Chicago, Illinois, United States
Unnamed facility
Augusta, Maine, United States
Unnamed facility
Boston, Massachusetts, United States
Unnamed facility
Kansas City, Missouri, United States
Unnamed facility
Brooklyn, New York, United States
...and 41 more locations